Table 1. Characteristics of the included studies.
| Author, year Study | Country | Study design | N total (% males) | N Somatostatin therapy (% males) | N Control therapy (% males) | Age (mean ± SD) years old | Intervention | Control | Outcome(s) | Follow-up period |
|---|---|---|---|---|---|---|---|---|---|---|
| Ruggenenti et al., 2005 | Italy | Single-center crossover RCT | 12 (75) | 12 (75.0) | 12 (75.0) | 44.5 (35–58) † | Octreotide 40mg every 28 days | Placebo | TKV, eGFR | 6 months |
| van Keimpema et al., 2009 (LOCK CYST) | Netherlands and Belgium | Multicenter parallel RCT | 54 (13) | 27 (11.1) | 27 (14.8) | Intervention: 49.6 (34.4–64.8) ‡ | Lanreotide 120mg every 28days | Placebo | TLV, TKV | 6 months |
| Control: 50.3 (32.6–68.1) ‡ | ||||||||||
| Caroli et al., 2010 | Italy | Multicenter crossover RCT | 12 (75) | 12 (75) | 12 (75) | 44.5 (35–58) † | Octreotide 40mg every 28 days | Placebo | TLV, TKV | 6 months |
| Hogan et al., 2010 | USA | Single-center parallel RCT | 42 (14.3) | 28 (17.9) | 14 (7.1) | 49.9 ± 8.38 | Octreotide 40mg every 28 days | Placebo | TLV, TKV, eGFR, QoL | 1 year |
| Caroli et al., 2013 (ALADIN) | Italy | Multicenter parallel RCT | 79 (46.8) | 40 (42.5) | 39 (51.3) | 36.98 ± 8.0 | Octreotide 40mg every 28 days | Placebo | TKV, eGFR | 3 years |
| Pisani et al., 2016 | Italy | Multicenter parallel RCT | 27 (37) | 14 (36) | 13 (38) | 33.37 ± 8.61 | Octreotide 40mg every 28 days | Placebo | TLV | 3 years |
| Meijer et al., 2018 (DIPAK 1) | Netherlands | Multicenter parallel RCT | 305 (46.6) | 153 (46.4) | 152 (46.7) | 48.34 ± 7.29 | Lanreotide 120mg every 28days | Standard care only | eGFR | 2.3 years |
| TKV | ||||||||||
| QoL | ||||||||||
| Perico et al., 2019 (ALADIN 2) | Italy | Multicenter parallel RCT | 100 (57.0) | 51 (60.8) | 49 (53.1) | 49.33 ± 9.07 | Octreotide 40mg every 28 days | Placebo | TKV | 3 years |
| eGFR | ||||||||||
| Van Aerts et al., 2019 | Netherlands | Multicenter parallel RCT | 175 (45.7) | 93 (43.0) | 82 (48.8) | 48.15 ± 6.56 | Lanreotide 120mg every 28 days | Standard care only | htTLV, htTLKV, QoL | 2.3 years |
| Hogan et al., 2020 | USA | Single center randomized clinical trail | 48 (10.4) | 33 (6.1) | 15 (20.0) | 50.55 ± 8.37 | Pasireotide 60mg every 28 days | Placebo | % Change in TLV | 1 year |
* Median (IQR).
† Median (range).
‡ 95% CI. RCT = Randomized Controlled Trial. TLV = Total Liver Volume. TKV = Total Kidney Volume. eGFR = estimated Golmerular Filtration Rate. QoL = Quality of Life.